ANGIOPREDICT has eight scientific work packages, two of which are dedicated to collecting and distributing retrospective and prospective samples.

Work Package 2: Biorepository

Retrospective (previously-collected) tissue samples from RCSI and UHEI and prospective (newly collected, during the project) samples from the AC-ANGIOPREDICT clinical trial will be stored in a central ANGIOPREDICT biorepository located at UHEI. These samples will be distributed to ANGIOPREDICT partners for analysis in other work packages throughout the project. Oversight of sample coding and clinical data collation will be provided by ICORG.

Work Package 3: Genomic Biomarker Focused Phase 2 Clinical Study: AC-ANGIOPREDICT Trial

A multi-centre, Phase 2 clinical trial, co-ordinated by ICORG and VUMC, will be carried out in clinical centres in Germany, including UHEI, and across the island of Ireland. Metastatic colorectal cancer (mCRC) patients expressing mutant k-ras will receive oxaliplatin plus infusional floururacil/leucovorin (FOLFOX) in combination with bevacizumab (bvz, Avastin®) as first line treatment. The primary objective of the trial is to identify and validate genomic markers for combination bvz therapy and assess their value as response predictors in K-ras mutant mCRC. Secondary objectives are to test the efficacy of bvz in combination with FOLFOX in patients with newly diagnosed mCRC k-ras mutant colorectal cancer and to determine the progression free and overall survival of patients under first line FOLFOX+/- bvz in mCRC.